Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.70 |
| ▸ | NAAA | Q02083 | 1/20 | 0.66 |
| ▸ | FAAH | O00519 | 3/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537985 | 0.98 | CASP2 (0.74) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL937406 | 0.98 | CASP2 (0.74) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL28420676 | 0.98 | CASP2 (0.74) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL295180 | 0.94 | CASP2 (0.61) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL3033459 | 0.88 | CASP2 (0.66) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL7346940 | 0.88 | CASP2 (0.66) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL5539151 | 0.88 | CASP2 (0.71) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL10443771 | 0.86 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL10895513 | 0.86 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL5541786 | 0.86 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4818754-A | ANTIALLERGENS | BEECHAM GROUP P.L.C. OF BEECHAM HOUSE (GB) | 1989-04-04 | — | — | US | claimed |
| EP-0243055-A2 | Pyrazolopyridine derivatives, process for their preparation, and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1987-10-28 | — | — | EP | claimed |
| US-7956182-B2 | Process for preparing optically active alcohols | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1988071-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE ALCOHOL | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-4818754-A | ANTIALLERGENS | BEECHAM GROUP P.L.C. OF BEECHAM HOUSE (GB) | 1989-04-04 | — | — | US | disclosed |
| EP-0243055-A2 | Pyrazolopyridine derivatives, process for their preparation, and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | ADH1C, ADH1A, ADH5 | CASP2 3828/4885NAAA 2855/4885FAAH 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.